ArticleTranslational andrology and urology2026
Holmium laser enucleation of the prostate improves the renal insufficiency of benign prostatic hyperplasia with hydronephrosis.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hydronephrosis is a serious long-term complication of benign prostatic hyperplasia (BPH), and patients with this condition are prone to suffer from renal insufficiency. This study was performed to evaluate the efficacy of holmium laser enucleation of the prostate (HoLEP) for renal dysfunction in BPH patients with hydronephrosis. Methods: In this retrospective cohort study, the enrolled 122 patients were divided into two groups according to the type of surgery: HoLEP (n=64) or bipolar plasmakinetic transurethral resection of the prostate (TURP, n=58). Perioperative indicators and follow-up variables were analysed to evaluate the efficacy and durability of HoLEP. Results: The HoLEP group had a shorter operation time, bladder irrigation time, catheterization duration and hospital stays; less haemoglobin (Hb) and sodium decrease; and greater tissue removal (P<0.01). Improvements in the International Prostate Symptom Score (I-PSS), postvoid residual, maximum urinary flow rate, hydronephrosis and renal dysfunction in the HoLEP group were more evident during the entire follow-up period (P<0.01). Conclusions: Therefore, by more safely and completely removing the hyperplastic prostate tissue to ensure durable relief of lower urinary tract obstruction, HoLEP can effectively and continuously benefit the recovery of renal function in BPH patients with preoperative hydronephrosis, and it is expected to become the ideal surgical intervention for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.